Asciminib Gets Accelerated Approval for Ph+ CML
The FDA granted an accelerated approval to asciminib for newly diagnosed Ph+ chronic myeloid leukemia in the chronic phase.
The FDA granted an accelerated approval to asciminib (Scemblix) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) that is in chronic phase, according to an announcement from the agency.1
The approval is based off findings from the multicenter, randomized, active-controlled, open-label ASC4FIRST trial (NCT04971226), in which 405 patients were randomized 1:1 to receive either asciminib or investigator’s choice of a selected tyrosine kinase inhibitor (TKI). Investigators could choose from the following TKIs: imatinib (Gleevec), nilotinib (Tasigna), dasatinib (Sprycel), or bosutinib (Bosulif).
READ MORE: Asciminib Has Superior Response Rates in CML
Major molecular response (MMR) at 48 weeks—the trial’s main efficacy outcome—was 68% (95% CI, 61-74) in the asciminib arm, compared with 49% (95% CI, 42-56) in the TKI arm (p value < 0.001). MMR rates were 69% (95% CI, 59-78) and 40% (95% CI, 31-50) in the asciminib and TKI groups, respectively (p-value <0.001).2
In a pooled safety population that included patients with newly diagnosed and previously treated Ph+ CML in chronic phase, the most common adverse effects that occurred in 20% or more of patients were musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea.
Meanwhile, common laboratory abnormalities that occurred in 40% or more of patients were: lymphocyte count, decreased leukocyte count, decreased platelet count, decreased neutrophil count, and decreased calcium corrected.
According to the FDA, recommended asciminib dosing is 80 mg once per day or 40 mg twice per day at approximately 12-hour intervals.
References
1. FDA. FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia. October 29, 2024. Accessed October 29, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia
2. Hochhaus A, Wang J, Kim DW, et al; ASC4FIRST Investigators. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885-898. doi:10.1056/NEJMoa2400858
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.
